Zobrazeno 1 - 10
of 63
pro vyhledávání: ''
Autor:
Ruihua Bai, Tianshun Zhang, Yongping Song, Qingxin Xia, Kangdong Liu, Zigang Dong, Qiushi Wang, Xiang Li, Keke Wang, Xiaoyu Chang, Ting Wang, Ann M. Bode, Joohyun Ryu, Wei-Ya Ma
Publikováno v:
Cancer Prevention Research. 12:837-848
Lung cancer is the leading cause of cancer-related death worldwide. However, promising agents for lung cancer prevention are still very limited. Identification of preventive targets and novel effective preventive agents is urgently needed for clinica
Autor:
Thomas Roeder, Lia Burkhardt, Judith Bossen, Line Steen, Iris Bruchhaus, Karin Uliczka, Christine Fink, Mandy Mong-Quyen Mai, Roxana Pfefferkorn, Michael Spohn, Holger Heine
Publikováno v:
Molecular Cancer Therapeutics. 18:1659-1668
Lung cancer is the leading cause of cancer-associated mortality. Mutations in the EGFR gene are among the most important inducers of lung tumor development, but success of personalized therapies is still limited because of toxicity or developing resi
Autor:
Rebecca J. Nagy, Paul A. VanderLaan, Bryan C. Ulrich, Stephen Wang, Magda Bahcall, Giulia Costanza Leonardi, Emily S. Chambers, Man Xu, Marzia Capelletti, Jihyun Choi, Richard B. Lanman, Mark M. Awad, Amanda J. Redig, Hideo Baba, Paul Kirschmeier, Yu Imamura, Elena Ivanova, Frederick H. Wilson, Lynette M. Sholl, Cloud P. Paweletz, Masayuki Watanabe, Sangeetha Palakurthi, Pasi A. Jänne, Mizuki Nishino, Daniel B. Costa
Publikováno v:
Clinical Cancer Research. 24:5963-5976
Purpose: MET inhibitors can be effective therapies in patients with MET exon 14 (METex14) mutant non–small cell lung cancer (NSCLC). However, long-term efficacy is limited by the development of drug resistance. In this study, we characterize acquir
Autor:
Si-Yang Liu, Qing Zhou, Lan-Ying Gou, A. Li, Zhi-Hong Chen, Bin Gan, Hua-Jun Chen, Bin-Chao Wang, Jian Su, Chong-Rui Xu, Qi Zhang, Jin-Ji Yang, Zheng Wang, Xue-Ning Yang, Zhenfan Yang, Shannon Chuai, Han Han-Zhang, Zhen Wang, Zhi Xie, Wen-Zhao Zhong, Zhou Zhang, Yu Bai, Xu-Chao Zhang, Si-Pei Wu, Ben-Yuan Jiang, Hong-Fei Gao, Yi-Long Wu
Publikováno v:
Clinical Cancer Research. 23:4929-4937
Purpose: MET amplification, responsible for 20% of acquired resistance to EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non–small cell lung cancer (NSCLC), presents an attractive target. Numerous studies have conferred susceptibili
Autor:
Jens Meiler, Jonathan H. Sheehan, Timothy M. Shaver, Jean-Nicolas Gallant, Sally York, Mark G. Kris, Jennifer A. Pietenpol, Marc Ladanyi, Siraj M. Ali, Christine M. Lovly, Monica Red Brewer, Vincent A. Miller, Doron Lipson, Mark Bailey, Raghu Chandramohan
Publikováno v:
Cancer Discovery. 5:1155-1163
Oncogenic EGFR mutations are found in 10% to 35% of lung adenocarcinomas. Such mutations, which present most commonly as small in-frame deletions in exon 19 or point mutations in exon 21 (L858R), confer sensitivity to EGFR tyrosine kinase inhibitors
Publikováno v:
Cancer Research. 80:4490-4490
Objective: Lung cancer is one of the leading causes of cancer-related mortality in the world, and non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers. With the emergence of epidermal growth factor receptor tyrosine k
Publikováno v:
Molecular Cancer Research. 18:A37-A37
Lung cancer is the leading cause of cancer death worldwide, and it is estimated that 1.6 million deaths occur per year. Non-small cell lung cancer (NSCLC), mainly consisting of adenocarcinoma and squamous cell carcinoma, accounts for more than 80% of
Autor:
Daniel B. Costa, Susumu Kobayashi, Sohei Nakayama, Julian Carretero, Hiroyuki Yasuda, Alistair J. Tan, Ross A. Soo, Mihoko Yamamoto, Kenzo Soejima, Norihiro Yamaguchi, Danan Li, Kwok-Kin Wong, Robert S. Welner, Yuichiro Hayashi, Natasha J. Sng
Publikováno v:
Cancer Research. 74:5891-5902
The discovery of somatic mutations in EGFR and development of EGFR tyrosine kinase inhibitors (TKI) have revolutionized treatment for lung cancer. However, resistance to TKIs emerges in almost all patients and currently no effective treatment is avai
Autor:
Randal May, Dongfeng Qu, Janani Panneerselvam, Courtney W. Houchen, Nathaniel Weygant, Naushad Ali, Michael S. Bronze, Chinthalapally V. Rao, Priyanga Mohandoss, Timothy C. Wang, Parthasarathy Chandrakesan
Publikováno v:
Cancer Research. 79:2119-2119
Background: Lung cancer is the deadliest cancer in both men and women. About 85% of lung cancers are non-small cell lung cancer (NSCLC) and almost 25% of all types of NSCLC contain KRAS mutations, which remain as an undruggable challenge. Doublecorti
Publikováno v:
Cancer Research. 79:1281-1281
The emergence of the T790M gatekeeper mutation in the Epidermal Growth Factor Receptor (EGFR) gene is an important mechanism that can lead to the acquired resistance to EGFR-targeted tyrosine kinase inhibitors used in a subset of non-small cell lung